Ignite Creation Date:
2025-12-24 @ 7:30 PM
Ignite Modification Date:
2025-12-25 @ 5:12 PM
Study NCT ID:
NCT03890003
Status:
COMPLETED
Last Update Posted:
2019-06-05
First Post:
2019-03-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
An Early Feasibility Study to Evaluate the Predictive Low Glucose Suspend Functionality and Safety in an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2019-06-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
True
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| F3Z-MC-IORC | OTHER | Eli Lilly and Company | View |